Breast cancer -- improved diagnostic accuracy and treatment targeting

November 25, 2015

Following a kick-off meeting, the TransLUMINAL-B project, which is being led by Charité -- Universitätsmedizin Berlin, is now officially underway. Over the next three years, researchers involved in the project will study the process of metastasis formation and the role of malignant cells, which accumulate in the blood and bone marrow of patients with certain types of breast cancer.

The project is being supported with €2 million in funding from German Cancer Aid, which was awarded as part of its 'Translational Oncology' priority program.

In Germany, 72,000 women develop breast cancer every year. The current project is setting out to study the most common type of the disease, luminal breast cancers, which account for 70 to 80% of all breast cancer cases. Luminal breast cancers are hormone-sensitive, and are usually treated with hormone therapy drugs; in many cases, this approach is effective. However, there are some exceptions, with one group in particular associated with a high level of risk. Many of the cancers in this group are resistant to therapy, which leads to recurrence and metastases.

While things may start off with only a tiny number of cancer cells being found in the blood and bone marrow, it is these few cells which play a crucial role in how the cancer spreads. As part of the TransLUMINAL-B project, and in order to gain a better understanding of the mechanisms involved, Prof. Dr. Carsten Denkert and his research team at Charité's Institute of Pathology will be investigating changes in individual cancer cells taken from the blood and bone marrow. The researchers are hoping to find out how and why they spread through the body, and why they have so far proven resistant to current treatments. "Once we have established the special characteristics of individual malignant cells from the blood, we will investigate the cells inside the cancer's tissue, and then compare the two," explains Prof. Carsten Denkert. "We hope that this will make it possible, even at first diagnosis, to predict whether a specific cancer is likely to metastasize, and whether it is likely to have a bad prognosis." This knowledge will allow physicians to treat cancers in a more targeted way, saving valuable time.

The German Cancer Aid Translational Oncology Priority Program

German Cancer Aid set up the Translational Oncology Priority Program in 2014 in order to speed up the translation of laboratory findings into clinical practice. The term 'translational oncology' refers to the interface between oncology research and its practical application, meaning that patients should be able to benefit quickly, with laboratory findings turned into improved diagnostic and treatment methods.

The TransLUMINAL-B project

The TransLUMINAL-B project, which is being led and coordinated by Prof. Dr. Carsten Denkert, is being conducted at the Institute of Pathology at Charité - Universitätsmedizin Berlin. The partners involved in the project are: the German Cancer Research Center in Heidelberg (Prof. Dr. Andreas Trumpp), the University of Heidelberg Institute of Pathology (Prof. Dr. Wilko Weichert), Universität Regensburg (Prof. Dr. Gero Brockhoff and Prof. Dr. Christoph Klein), and the German Breast Group (Prof. Dr. Sibylle Loibl).
-end-
Contact:
Prof. Dr. Carsten Denkert
Institute of Pathology
Charité - Universitätsmedizin Berlin
Tel: +49 (30) 450 536 047
Email: carsten.denkert@charite.de

Charité - Universitätsmedizin Berlin

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.